open access

Vol 14, No 2 (2018)
Guidelines / Expert consensus
Published online: 2018-04-26
Get Citation

Chemotherapy- and radiotherapy-induced nausea and vomiting

Andrzej Kawecki, Maciej Krzakowski
DOI: 10.5603/OCP.2018.0010
·
Oncol Clin Pract 2018;14(2):53-61.

open access

Vol 14, No 2 (2018)
GUIDELINES FOR DIAGNOSTIC AND THERAPEUTIC MANAGEMENT IN MALIGNANT NEOPLASMS 2018
Published online: 2018-04-26

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Chemotherapy- and radiotherapy-induced nausea and vomiting

Journal

Oncology in Clinical Practice

Issue

Vol 14, No 2 (2018)

Article type

Guidelines / Expert consensus

Pages

53-61

Published online

2018-04-26

DOI

10.5603/OCP.2018.0010

Bibliographic record

Oncol Clin Pract 2018;14(2):53-61.

Authors

Andrzej Kawecki
Maciej Krzakowski

References (13)
  1. Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol. 2008; 5(1): 32–43.
  2. Basch E, Prestrud AA, Hesketh P, et al. Antiemetics: American Society of ical ogy ical Practice Guideline Update. J Clin Oncol. 2011; 29: 4189–4198.
  3. Grunberg SM, Warr D, Gralla RJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art. Support Care Cancer. 2011; 19 Suppl 1: S43–S47.
  4. Roila F, Molassiotis A, Herrstedt J, et al. participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016; 27(suppl 5): v119–v133.
  5. Hesketh PJ, Bohlke K, Lyman GH, et al. American Society of Clinical Oncology. Antiemetics: American Society of Clinical Oncology Focused Guideline Update. J Clin Oncol. 2016; 34(4): 381–386.
  6. Dranitsaris G, Molassiotis A, Clemons M, et al. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol. 2017; 28(6): 1260–1267.
  7. Jordan K, Hinke A, Grothey A, et al. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer. 2007; 15(9): 1023–1033.
  8. Billio A, Morello E, Clarke MJ. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults. Cochrane Database Syst Rev. 2010(1): CD006272.
  9. Botrel TE, Clark OA, Clark L, et al. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer. 2011; 19(6): 823–832.
  10. dos Santos LV, Souza FH, Brunetto AT, et al. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst. 2012; 104(17): 1280–1292.
  11. Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol. 2015; 26(6): 1081–1090.
  12. Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016; 375(2): 134–142.
  13. Ruhlmann CH, Jahn F, Jordan K, et al. MASCC/ESMO. Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines. Support Care Cancer. 2005; 13(2): 122–128.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl